Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: A case study

Pharmaceutical Statistics

Volumn 14, Issue 3, 2015, Pages 205-215

  Walley, Rosalind J ^a   Smith, Claire L ^b   Gale, Jeremy D ^c   Woodward, Phil ^d  

^a UCB PHARMA   (Belgium)

^b ELI LILLY AND COMPANY   (United States)

^c MA   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

assurance; Bayesian inference; interim analysis; operating characteristics; pre posterior distribution

Indexed keywords

ARTICLE; BAYES THEOREM; CASE STUDY; CHRONIC KIDNEY DISEASE; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; NORMAL DISTRIBUTION; PLACEBO EFFECT; PREDICTIVE VALUE; PROBABILITY; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; STUDY DESIGN; ALBUMINURIA; BLOOD; METHODOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; STANDARDS; STATISTICS; TREATMENT OUTCOME;

CREATININE;

ALBUMINURIA; BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; CREATININE; HUMANS; MODELS, STATISTICAL; PLACEBO EFFECT; PROBABILITY; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 84929130868     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1675     Document Type: Article

References (29)

1. Bunnage ME,. Getting pharmaceutical R&D back on target. Nature Chemical Biology 2011; 7: 335-339.
2. Paul SM, Mytelko DS, Dunwiddie CT, Persinger CC, Munos BH, Linborg SR, Schacht AL,. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews 2010; 9: 203-214.
3. Arrowsmith J,. Phase II failures: 2008-2010. Nature Reviews Drug Discovery 2011; 10: 328-329.
4. Berry DA,. Bayesian clinical trials. Nature Reviews 2006; 5: 27-36.
5. Mallinckrodt CH, Tamura RN, Tanaka Y,. Recent developments in improving signal detection and reducing placebo response psychiatric clinical trials. Journal of Psychiatric Research 2011; 45: 1202-1207.
6. Lindley DV,. Making decisions (2nd edn). John Wiley & Sons: New York, USA, 1985.
7. O'Hagan A, Stevens JW, Campbell MJ,. Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4: 187-201.
8. Woodward P,. Bayesian Analysis Made Simple: An Excel GUI for WinBUGS, Biostatistics Series. Chapman & Hall/CRC: Boca Raton, 2011.
9. Neuenschwander B, Capkun-Niggli G, Branson M, Speiegelhalter DJ,. Summarizing historical information on controls in clinical trials. Clinical Trials 2010; 7: 5-18.
10. Di Scala L, Kerman J, Neuenschwander B,. Collection, synthesis, an interpretation of evidence: a proof-of-concept study in COPD. Statistics in Medicine 2013; 32: 1621-1634.
11. Chen M-H, Ibrahim JG,. Power prior distributions for regression models. Statistics Science 2000; 15: 46-60.
12. Eddy D, Hasselblad V, Schachter R,. Meta-analysis by the Confidence Profile Method: The Statistical Synthesis of Evidence. Academic Press: San Diego, CA, 1992.
13. O'Hagan A, Buck CE, Daneshkhah A, Eiser JE, Garthwaite PH, Jenkinson DJ, Oakley JE, Rakow T,. Uncertain Judgements: Eliciting Expert Probabilities. Wiley: Chichester, 2006.
14. Evans M, Hastings N, Peacock B,. Statistical Distributions (3rd edn). Wiley: New York, 2000.
15. Dmitrienko A, Wang M-D,. Bayesian predictive approach to interim monitoring in clinical trials. Statistics in Medicine 2006; 25: 2178-2195.
16. Freedman LS, Spiegelhalter DJ,. Application of Bayesian statistics to decision making during a clinical trial. Statistics in Medicine 1992; 11: 23-35.
17. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS,. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutritional Examination Survey. American Journal of Kidney Disease 2003; 41: 1-12.
18. Lameire N, Jager K, Van Biesen W, De Bacquer D, Vanholder R,. Chronic kidney disease: a European persepective. Kidney International 2005; 68 (Suppl. 99): S30-S38.
19. Khwaja A, el Kossi M, Floeg J, El Nahas M,. The management of CKD: a look into the future. Kidney International 2007; 72: 1316-1323.
20. Box GEP, Tiao GC,. A Bayesian approach to some outlier problems. Biometrika 1968; 55 (1): 119-129.
21. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK,. Aliskiren combined with losartan in type 2 diabetes and nephropathy. The New England Journal of Medicine 2008; 358: 2433-2446.
22. Mann JFE, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G, ASCEND Study Group,. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. Journal of the American Society of Nephrology 2010; 21: 527-535.
23. De Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM,. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney International 2004; 65: 2309-2320.
24. Evans M, Moshonov H,. Checking for prior-data conflict. Bayesian Analysis 2006; 1: 893-914.
25. Bolstad W,. Introduction to Bayesian statistics. John Wiley & Sons Inc.: Hoboken, New Jersey, 2004.
26. Woodward P,. BugsXLA: Bayes for the common man. Journal of Statistical Software 2005; 14, 5, Available at http://www.jstatsoft.org/v14/i05 (accessed 18.03.2015).
27. R Core Team,. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013. Available at: http://www.Rproject.org/ (accessed 18.03.2015).
28. Lunn DJ, Thomas A, Best N, Spiegelhalter DJ,. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10: 325-337.
29. Lindley DV, Smith AFM,. Bayes estimates for the linear model. Journal of the Royal Statistical Society Series B 1972; 34: 1-41.